



Corrigendum: The Therapeutic Principle of Combined Strengthening Qi and Eliminating Pathogens in Treating Middle-Advanced Primary Liver Cancer: A Systematic Review and Meta-Analysis

Yingqi She^{1†}, Qinfeng Huang^{2†}, Zhen Ye¹, Yu Hu¹, Mingquan Wu³, Kaihua Qin⁴, Ailing Wei⁵, Xin Yang¹, Yuyao Liu⁶, Cuihan Zhang⁶ and Qiaobo Ye^{1*}

¹School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China, ²Department of Oncology, The First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning, China, ³Department of Pharmacy, Sichuan Provincial Orthopedic Hospital, Chengdu, China, ⁴Health Preservation and Rehabilitation College, Chengdu University of Traditional Chinese Medicine, Chengdu, China, ⁵Department of Liver Disease, The First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning, China, ⁶Pharmacy College, Chengdu University of Traditional Chinese Medicine, Chengdu, China

OPEN ACCESS

Approved by:

Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*Correspondence:

Qiaobo Ye
yeqiaobo@cducm.edu.cn

[†]These authors contributed equally to
this work

Specialty section:

This article was submitted to
Ethnopharmacology,
a section of the journal
Frontiers in Pharmacology

Received: 31 December 2021

Accepted: 18 January 2022

Published: 04 February 2022

Citation:

She Y, Huang Q, Ye Z, Hu Y, Wu M, Qin K, Wei A, Yang X, Liu Y, Zhang C and Ye Q (2022) Corrigendum: The Therapeutic Principle of Combined Strengthening Qi and Eliminating Pathogens in Treating Middle-Advanced Primary Liver Cancer: A Systematic Review and Meta-Analysis. *Front. Pharmacol.* 13:846668. doi: 10.3389/fphar.2022.846668

Keywords: Chinese medicinal formulas, transcatheter arterial chemoembolization, drastic medicinals, therapeutic principle, primary liver cancer, meta-analysis

A Corrigendum on

The Therapeutic Principle of Combined Strengthening Qi and Eliminating Pathogens in Treating Middle-Advanced Primary Liver Cancer: A Systematic Review and Meta-Analysis by She, Y., Huang, Q., Ye, Z., Hu, Y., Wu, M., Qin, K., Wei, A., Yang, X., Liu, Y., Zhang, C. and Ye, Q. (2021). *Front. Pharmacol.* 12:714287. doi: 10.3389/fphar.2021.714287

In the published article, there was an error in **affiliation 2**. Instead of “Department of Oncology, The First Affiliated Hospital, Guangxi University of Chinese Medicine, Chengdu, China”, it should be “Department of Oncology, The First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning, China”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 She, Huang, Ye, Hu, Wu, Qin, Wei, Yang, Liu, Zhang and Ye. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.